Table 1.
Characteristics | No of patients (n = 14) | Percent |
---|---|---|
Gender | ||
Male | 6 | 42.9 |
Female | 8 | 57.1 |
Age, median (range)/years | 56.5 (14-81) | |
Performance status (ECOG) | ||
0–1 | 13 | 92.9 |
2 | 1 | 7.1 |
Stage at diagnosis (Masaoka-Koga) | ||
IVa | 3 | 21.4 |
IVb | 8 | 57.1 |
Recurrence | 3 | 21.4 |
Metastatic sites (overlapped) | ||
Lung | 6 | |
Liver | 2 | |
Lymph nodes | 5 | |
Pleura | 5 | |
Bone | 3 | |
Brain | 1 | |
Histologic subtype | ||
Squamous cell carcinoma | 12 | 85.7 |
Lymphoepithelioma-like carcinoma | 1 | 7.1 |
Undifferentiated carcinoma | 1 | 7.1 |
Previous chemotherapy | ||
ADOC | 3 | |
Cisplatin-irinotecan | 9 | |
Cisplatin-gemcitabine | 1 | |
Carboplatin-gemcitabine | 1 |
No number, ADOC cisplatin, adriamycin, vincristine, and cyclophosphamide